These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30730272)

  • 1. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
    Olson DJ; Luke JJ
    Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
    Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
    Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
    Spranger S
    Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
    Trujillo JA; Sweis RF; Bao R; Luke JJ
    Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.
    Phan TG; Long GV; Scolyer RA
    Immunol Cell Biol; 2015 Apr; 93(4):323-5. PubMed ID: 25686808
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
    Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
    Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL21 Programs Immune Activity in Tumor Microenvironment.
    Sharma S; Kadam P; Dubinett S
    Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.
    Casey DL; Cheung NV
    Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of immune escape in the cancer immune cycle.
    Tang S; Ning Q; Yang L; Mo Z; Tang S
    Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Reciprocity between Radiotherapy and Cancer Immunotherapy.
    Wang Y; Liu ZG; Yuan H; Deng W; Li J; Huang Y; Kim BYS; Story MD; Jiang W
    Clin Cancer Res; 2019 Mar; 25(6):1709-1717. PubMed ID: 30413527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction to checkpoint inhibitors and cancer immunotherapy.
    Sharpe AH
    Immunol Rev; 2017 Mar; 276(1):5-8. PubMed ID: 28258698
    [No Abstract]   [Full Text] [Related]  

  • 12. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
    Zhao Y; Shao Q; Peng G
    Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recruiting T cells in cancer immunotherapy.
    Yost KE; Chang HY; Satpathy AT
    Science; 2021 Apr; 372(6538):130-131. PubMed ID: 33833111
    [No Abstract]   [Full Text] [Related]  

  • 14. Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy.
    Schmittnaegel M; De Palma M
    Trends Cancer; 2017 Dec; 3(12):809-812. PubMed ID: 29198436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
    Li X; Xiang Y; Li F; Yin C; Li B; Ke X
    Front Immunol; 2019; 10():2293. PubMed ID: 31616443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of microenvironment on tumor immunotherapy.
    Zhang J; Shi Z; Xu X; Yu Z; Mi J
    FEBS J; 2019 Nov; 286(21):4160-4175. PubMed ID: 31365790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
    Fridman WH; Petitprez F; Sautes-Fridman C
    Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
    [No Abstract]   [Full Text] [Related]  

  • 18. T cells and cancer - why do the killers become exhausted?
    Brück O; Keränen M; Dufva O; Kreutzman A; Mustjoki S
    Duodecim; 2016; 132(21):1984-92. PubMed ID: 29190050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: Cancer Immunology Special Issue-Immunopathology.
    Kawakami Y
    Int Immunol; 2016 Aug; 28(8):371. PubMed ID: 27450690
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptides that immunoactivate the tumor microenvironment.
    Furukawa N; Popel AS
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188486. PubMed ID: 33276025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.